Immunovant, Inc. 4

Director Atul Pande exercised 1,500 Immunovant, Inc. stock options at $8.43 and sold 1,500 common shares at $39.80 pursuant to a Rule 10b5-1 plan.

On July 24, 2026, Immunovant, Inc. director Atul Pande exercised 1,500 stock options at $8.43 per share, acquiring 1,500 shares of common stock, and on the same day sold 1,500 shares at $39.80 per share under a pre-arranged Rule 10b5-1 trading plan, effectively realizing the spread between the exercise and sale prices. The option exercise added 1,500 shares to his direct holdings (reflected as 118,231 shares after the acquisition), while the subsequent sale reduced his direct holdings to 116,731 shares. In addition, he continues to hold 20,000 shares of common stock indirectly through a trust and 1,500 option shares remaining (shown as a derivative security position with 1,500 underlying shares and an exercise price of $8.43, expiring November 19, 2029). Based on the reported prices, the option exercise cost approximately $12,645 and the sale generated about $59,700, implying an economic gain of roughly $47,055 before taxes, and his remaining direct equity stake is valued at roughly $4.64 million using the $39.80 reference price.

Filing Facts

CIK

1764013

Ticker

IMVT

Form

4

Source Type

fda

Accession

0001643071-26-000007

Alert Tier

6